Stability indicating validated HPLC method for quantification of levothyroxine with eight degradation peaks in the presence of excipients

International Journal of Pharmaceutics

Volumn 360, Issue 1-2, 2008, Pages 77-82

  Shah, R B ^a   Bryant, A ^a   Collier, J ^a,b   Habib, M J ^b   Khan, M A ^a  

^a Office of Testing and Research   (United States)

^b HOWARD UNIVERSITY   (United States)

Author keywords

Degradation products; Excipients; Impurities; Levothyroxine; Validation

Indexed keywords

ACETONITRILE; AEROSIL; BUTYLATED HYDROXYANISOLE; CROSCARMELLOSE SODIUM; CROSPOVIDONE; DIIODOTHYRONINE; DIIODOTYROSINE; DODECYL SULFATE SODIUM; GUM ARABIC; IODOTYROSINE; LACTOSE; LEVOTHYROXINE; LIOTHYRONINE; MAGNESIUM STEARATE; MANNITOL; METHANOL; MICROCRYSTALLINE CELLULOSE; POVIDONE; SILICON DIOXIDE; SODIUM HYDROXIDE; SUCROSE; SUGAR; TALC; TETRAIODOTHYROACETIC ACID; THEOPHYLLINE; THYRONINE; THYROXINE; TIRATRICOL; TRIFLUOROACETIC ACID; TYROSINE; UNINDEXED DRUG;

ACCURACY; ARTICLE; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY;

CALIBRATION; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; DRUG STABILITY; EXCIPIENTS; HYDROLYSIS; QUALITY CONTROL; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SPECTROPHOTOMETRY, ULTRAVIOLET; THYROXINE;

EID: 47249109317     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.04.018     Document Type: Article

References (18)

1. Bakshi M., and Singh S. Development of validated stability-indicating assay methods-critical review. J. Pharm. Biomed. Anal. 28 (2002) 1011-1040
2. Bakshi M., Ojha T., and Singh S. Validated specific HPLC methods for determination of prazosin, terazosin and doxazosin in the presence of degradation products formed under ICH-recommended stress conditions. J. Pharm. Biomed. Anal. 34 (2004) 19-26
3. FDA CDER (1994). Reviewer Guidance, Validation of chromatographic methods. FDA.
4. FDA. Regulatory History and Current Issues (2006), Dept. Health Human Ser.
5. Garnick R.L., Burt G.F., Long D.A., Bastian J.W., and Aldred J.P. High-performance liquid chromatographic assay for sodium levothyroxine in tablet formulations: content uniformity applications. J. Pharm. Sci. 73 (1984) 75-77
6. Gika H.G., Samanidou V.F., and Papadoyannis I.N. Development of a validated HPLC method for the determination of iodotyrosines and iodothyronines in pharmaceuticals and biological samples using solid phase extraction. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 814 (2005) 163-172
7. Graham J.H., Banes D., Biesemeyer M.E., and Nadkarni A. Analysis of sodium levothyroxine or sodium liothyronine in tablets. J. Pharm. Sci. 63 (1974) 763-766
8. ICH Q2 (R1). Validation of analytical procedures: text and methodology. Proceedings of the International Conference on Harmonization (1995)
9. ICH Q1A (R2). Stability testing of new drug substances and products. Proceedings of the International Conference on Harmonization (2003)
10. Ojha T., Bakshi M., Chakraborti A.K., and Singh S. The ICH guidance in practice: stress decomposition studies on three piperazinyl quinazoline adrenergic receptor-blocking agents and comparison of their degradation behaviour. J. Pharm. Biomed. Anal. 31 (2003) 775-783
11. Patel H., Stalcup A., Dansereau R., and Sakr A. The effect of excipients on the stability of levothyroxine sodium pentahydrate tablets. Int. J. Pharm. 264 (2003) 35-43
12. Rapaka R.S., Knight P.W., and Prasad V.K. Reversed-phase high-performance liquid chromatographic analysis of liothyronine sodium and levothyroxine sodium in tablet formulations: preliminary studies on dissolution and content uniformity. J. Pharm. Sci. 70 (1981) 131-134
13. Richheimer S.L., and Amer T.M. Stability-indicating assay, dissolution, and content uniformity of sodium levothyroxine in tablets. J. Pharm. Sci. 72 (1983) 1349-1351
14. Smith D.J., Biesemeyer M., and Yaciw C. The separation and determination of liothyronine and levothyroxine in tablets by reversed-phase high performance liquid chromatography. J. Chromatogr. Sci. 19 (1981) 72-78
15. Takahashi M., Nagashima M., Shigeoka S., Kamimura H., and Kamata K. Determination of thyroid hormones in pharmaceutical preparations, after derivatization with 9-anthroylnitrile, by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. A 958 (2002) 299-303
16. Thyroid Foundation of America. Thyroid Patient Advocacy Group Warns Thyroid Patients of Potential Problems with Thyroid Drug Resulting From FDA Approval of Generic Versions (2004), All Thyroid Org.: Thyroid Issues in the News
17. USP monograph, 2007 Levothyroxine Sodium. United States Pharmacopeia.
18. Won C.M. Kinetics of degradation of levothyroxine in aqueous solution and in solid state. Pharm. Res. 9 (1992) 131-137